Navigation Links
Cardiome To Release Second Quarter Results And Hold Conference Call
Date:8/11/2008

NASDAQ: CRME TSX: COM

VANCOUVER, Aug. 11 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced that it will report financial results for the second quarter ended June 30, 2008 on the afternoon of Tuesday, August 12, 2008. Cardiome will hold a teleconference call and webcast at 4:30pm Eastern (1:30pm Pacific) on that day to discuss the financial results and the recently-announced FDA action letter.

To access the conference call, please dial 416-641-6117 or 866-299-6655. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at http://www.cardiome.com.

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through September 12, 2008. Please dial 416-695-5800 or 800-408-3053 and enter code 3268411 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at http://www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Su
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. Cardiome Updates Guidance
7. Cardiome to Hold Investor Update Call
8. Cardiome And Astellas Announce Regulatory Update
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome To Release 2007 Results
11. Cardiome To Release 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 2Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 3Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 4Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 5Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 6Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 7Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 2Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 3Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 2Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 3Health News:2010 Will Be a Great Year for a Change! Start a New Career Now! 2
Breaking Medicine Technology:Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Cephalon Quarterly Conference Call Invitation 12853 1Police work undermines cardiovascular health comparison to general population shows 50430 1Police work undermines cardiovascular health comparison to general population shows 50430 2Police work undermines cardiovascular health comparison to general population shows 50430 3Bladder Cancer No Longer a Death Sentence 50427 1Bladder Cancer No Longer a Death Sentence 50427 2Bladder Cancer No Longer a Death Sentence 50427 3